Clinical trials
Advanced Solid Tumor Cancer clinical trials
Below are recruiting advanced solid tumor cancer clinical trials, each written for real people, not researchers. We’re tracking 1,356 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06943820RecruitingPhase 1/Phase 2
AK129 combination therapy for advanced solid tumors
This trial tests a new combination of drugs (including AK129) for people with advanced solid tumors, specifically lung cancer, head and neck cancer, or colorectal cancer. It is for those who have already tried a platinum chemo and a PD-1/PD-L1 drug but their cancer got worse.
Shenyang, LiaoningAges 18–75 - NCT06944457RecruitingPhase 1
Safety Study of MPD-1 for Advanced Solid Tumors
This trial tests a new drug called MPD-1 for people with advanced solid tumors that have not responded to standard treatments. It focuses on patients with specific genetic changes (KRAS mutation or PTEN loss) to see if the drug is safe and how the body processes it.
SeoulAges 19–75 - NCT06959615RecruitingPhase 1/Phase 2
Study of JAB-23E73 for KRAS-Altered Advanced Tumors
This trial tests an experimental pill (JAB-23E73) for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink or slow the growth of these cancers.
Hefei, AnhuiAges Any age - NCT06959706RecruitingPhase 1
Study of TGW101 for advanced solid tumors
This trial tests a new drug called TGW101 for people with certain advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and may help shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT06970795RecruitingPhase 1
Study of SYS6040 for advanced solid tumors
This trial tests a new drug called SYS6040 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
Changchuan, JilinAges 18 years+ - NCT06975410RecruitingPhase 1/Phase 2
Trial of YH32364 for EGFR-positive solid tumors
This trial tests a new drug, YH32364, for people with advanced solid tumors that have high levels of EGFR protein. It looks at whether the drug can help when standard treatments have stopped working.
SeoulAges 18 years+ - NCT06993844RecruitingPhase 1/Phase 2
Study of ETX-636 for advanced solid tumors with PIK3CA mutation
This trial tests an experimental drug called ETX-636 in people whose cancer has a specific gene change (PIK3CA mutation) and has not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Newport Beach, CaliforniaAges 18 years+ - NCT06997029RecruitingPhase 1
Study of BMS-986500 for advanced solid tumors
This trial tests a new drug called BMS-986500, alone or with other treatments, for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if the drug is safe and effective.
Birmingham, AlabamaAges 18 years+ - NCT07003022RecruitingPhase 2
Two-drug combo for advanced colorectal cancer
This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.
Shanghai, ChinaAges 18–80 - NCT07016997RecruitingPhase 1
A study of CBA-1535 for advanced solid tumors
This trial tests a new drug, CBA-1535, which is designed to help your immune system attack cancer cells. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
Nagaizumicho, ShizuokaAges 20 years+ - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for KRAS G12D solid tumors
This trial tests a new oral drug called VS-7375 for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07022002RecruitingPhase 2
Testing a new drug for HER2-positive advanced cancers
This trial tests a new drug called SSGJ-705, given alone or with other treatments, for advanced cancers that have a specific protein (HER2) on their surface. It is for people with lung, breast, or stomach cancer that has spread and hasn't gotten better with other treatments.
Hangzhou, ZhejiangAges 18–75 - NCT07029399RecruitingPhase 1
Study of NKT5097 for advanced solid tumors
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07030257RecruitingPhase 1/Phase 2
Study of CP-383 for advanced solid tumors
This study tests a new drug called CP-383 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors or slow cancer growth, especially for certain cancers with genetic changes.
Denver, ColoradoAges 18 years+ - NCT07030569Recruiting
Predicting treatment response in metastatic breast cancer
This trial studies how well CT and PET scans can predict if a certain type of breast cancer will respond to a targeted treatment. It focuses on women who had a biopsy of the liver, lung, or chest lining after the cancer spread.
MilanAges Any age - NCT07035249RecruitingPhase 1/Phase 2
DCSZ11 plus standard therapy for advanced solid tumors
This trial tests a new drug called DCSZ11 combined with usual chemotherapy and immunotherapy for people with advanced or metastatic solid tumors. It aims to see if adding DCSZ11 works better than standard treatments alone.
Chengdu, SichuanAges 18 years+ - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
Gilbert, ArizonaAges 18–75 - NCT07056556RecruitingPhase 1
Study of BL-M09D1 for advanced lung and other solid tumors
This trial tests a new drug, BL-M09D1, in people with advanced non-small cell lung cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07058948RecruitingPhase 2
Combining special radiation with immunotherapy for advanced cancer
This trial tests a new type of radiation combined with immunotherapy for people with advanced solid tumors that are no longer responding to standard treatments or cannot tolerate them. The goal is to see if this combination can help control the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07070518RecruitingPhase 1/Phase 2
Study of GV20-0251 for advanced solid tumors
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07080242RecruitingPhase 1
Study of a new drug for small cell lung cancer and neuroendocrine tumors
This trial tests a new drug called BL-M14D1 for people with certain types of advanced lung cancer or neuroendocrine tumors that have stopped responding to other treatments. It may be an option if your cancer has a specific marker called DLL3.
Huntsville, AlabamaAges 18 years+ - NCT07085091RecruitingPhase 1
Study of ALX2004 for advanced solid tumors
This trial tests a new drug, ALX2004, for people with certain advanced cancers (head and neck, lung, esophagus, or colorectal) that have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
Tampa, FloridaAges 18 years+ - NCT07086768RecruitingPhase 1
BSI-082 alone or with T-DXd for advanced solid tumors
This trial tests a new drug, BSI-082, alone or with another drug (T-DXd), for people with advanced solid tumors that no longer respond to standard therapy. It aims to find the best dose and check how well it works.
San Antonio, TexasAges 18 years+
Hear when a new Advanced Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid tumor cancer?
- Yes. Clin2 currently lists 1,356 recruiting advanced solid tumor cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid tumor cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.